Proximal Ventures Launches $27.5M Fund to Support AI in Drug Development Startups

Image: TechCrunch · Source

Sahir Raoof's new venture capital firm, Proximal Ventures, raises $27.5 million to invest in early-stage startups using AI to innovate pharmaceutical services and drug development processes.

In a challenging fundraising climate for first-time venture capital managers, Sahir Raoof has successfully raised $27.5 million for Proximal Ventures, his debut fund focused on startups that harness artificial intelligence to transform drug development. Raoof, previously a principal at SignalFire and an executive at healthcare startups including Iterative Health and Flatiron Health, aims to back companies offering AI-driven tools and services that could automate and streamline critical stages traditionally outsourced by pharmaceutical firms.

Pharmaceutical companies have long relied on specialized service providers for tasks such as synthesizing molecular compounds, scaling drug manufacturing, and analyzing clinical trial data. Raoof observes that while pharma has been more inclined to purchase services than software, AI now presents an opportunity to deliver these services faster and at lower costs, potentially reshaping an industry spending billions on external support.

Proximal Ventures plans to concentrate on pre-seed and seed stage investments, providing checks typically ranging from $500,000 to $1.5 million. Among its early portfolio companies is ChronicleBio, co-founded by former OpenAI executive Fidji Simo, which applies AI to analyze biological and medical data for better understanding chronic diseases and discovering new treatments.

Raoof's expertise in healthcare ecosystems and sales, alongside his extensive network, reassures limited partners about his ability to identify promising startups and assist them in building initial commercial momentum. Notable backers of Proximal Ventures include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors like Nan Li and Zavain Dar of Dimension Capital.

Amy Abernethy, co-founder of Highlander Health and former FDA principal deputy commissioner, also invests in Proximal and praises Raoof's capacity to forge industry relationships and identify key bottlenecks. She believes his insight into healthcare needs positions Proximal Ventures to achieve success and support disruptive innovation in pharmaceutical services.

By focusing on AI-enhanced solutions that can automate complex drug development activities, Proximal Ventures is positioning itself at the forefront of a growing intersection between artificial intelligence and pharmaceutical innovation, aiming to create significant efficiencies and cost reductions in the drug development pipeline.